Abstract
Prostate cancer is the second most commonly diagnosed malignancy in men; and in spite of recent therapeutic advances, it remains the fifth leading cause of male cancer deaths worldwide (1,2). Aside from prostatectomy and radiation, used with curative intent for the treatment of localized prostate cancer, approved life-prolonging treatment options for metastasized prostate cancer are limited to androgen receptor signaling inhibitors, microtubule targeting taxane chemotherapeutics, the bone targeted radioisotope Ra223, and active immunotherapy with sipuleucel-T (2). Hence, to improve prostate cancer care it is essential to identify novel treatment targets (3). Comprehensive genetic analyses have revealed a number of actionable molecular aberrations, including alterations of the PI3K-AKT and WNT signaling pathways, and DNA repair defects (4-6).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
